| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DCC2857 | Jrc-ii-191 | Novel inhibitor of CD4-gp120 binding, blocking the binding of the HIV-1 envelope glycoprotein gp120 to the CD4 receptor |
|
| DCC2858 | Js399-19 | Novel specific inhibitor of Fusarium myosin I; Fungicide |
|
| DCC2859 | Jsf-2019 | Novel antitubercular agent, inhibiting InhA and FAS-II pathway |
|
| DCC2860 | Jsf-2513 | Novel potent antitubercular agent, inhibiting InhA and FAS-II pathway |
|
| DCC2861 | Jsi287 | Novel ERK inhibitor, alleviating IMQ-induced mice skin lesions through ERK/IL-17 signaling pathway |
|
| DCC2862 | Jte-151 | Novel RORγ |
|
| DCC2863 | Jte-607 | Cytokine release inhibitor, inhibiting production of IL-1ß, IL-8, IL-6, IL-10 and TNFalpha |
|
| DCC2864 | Jtk-853 | Novel nonnucleoside inhibitor of the hepatitis C virus RNA-dependent RNA polymerase |
|
| DCC2865 | Jts-653 | Novel orally active and selective transient receptor potential vanilloid 1 (TRPV1) antagonist |
|
| DCC2866 | Jtt-552 | Novel inhibitor of urate transporter 1 (URAT1) |
|
| DCC2867 | jtv-506 | Novel K(ATP) channel opener |
|
| DCC2868 | Jtv-803 Mesylate | Specific inhibitor of factor Xa |
|
| DCC2869 | Julolidine Phenoxazone Azide | Novel live-cell peobe of voltage-dependent structural changes of voltage-gated Kv2.1 channels |
|
| DCC2870 | jwb1-84-1 Trihydrochloride | Novel neuroprotective agent, improving cognitive performances in a transgenic mouse model of AD |
|
| DCC2871 | Jwg-115 | Novel BET selective inhibitor, targeting BRD4 |
|
| DCC2872 | Jwh-007 | Potent cannabinoid (CB) receptor agonist |
|
| DCC2873 | Jwu-a021 | Novel potent stimulator of glucagon-like peptide-1 (GLP-1) secretion in vitro, also potently stimulating Ca(2+) influx through TRPA1 cation channels, being one of the most potent non-electrophilic TRPA-1 channel agonists |
|
| DCC2874 | Jxl069 | Novel potent mitochondrial pyruvate carrier (MPC) inhibitor to treat hair loss |
|
| DCC2875 | Jy-1-106 | Novel BH3 α-helix mimetic, inducing apoptosis in a subset of cancer cells (lung cancer, colon cancer and mesothelioma) by disrupting Bcl-xL and Mcl-1 protein-protein interactions with Bak |
|
| DCC2876 | Jyl-1511 | High-affinity partial agonist of the vanilloid receptor |
|
| DCC2877 | Jyl-273 | Potent TRPV1 agonist |
|
| DCC2878 | Jyl-79 | Potent vanilloid receptor (VR1) agonist |
|
| DCC2879 | Jy-xhe-053 | Selective modulator of GABAA receptors containing the α5 subunit |
|
| DCC2880 | Jz-4109 | Novel β-Glucocerebrosidase modulator, promoting dimerization of β-glucocerebrosidase and revealing an allosteric binding site, stabilizing wild-type and N370S mutant GCase and increases GCase abundance in patient-derived fibroblast cells |
|
| DCC2881 | Jz-5029 | Novel irreversible β-Glucocerebrosidase modulator |
|
| DCC2882 | jzad-iv-22 | Inhibitor of all three monoamine transporters |
|
| DCC2883 | Jzp-430 | Potent, highly selective, and irreversible ABHD6 Inhibitor |
|
| DCC2884 | K00135 | Novel potent and selective inhibitor of PIM kinases |
|
| DCC2885 | K00518 | Novel dual CLK1 and CLK3 inhibitor |
|
| DCC2886 | K103 Hydrochloride | Novel inhibitor of peptidoglycan synthesis targeting the lipid II precursor |
|
